Leflunomide: dermatologic perspective

References

• Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ. 1999;318:593–596.
   PubMed Web of Science ®Google Scholar
• Silva Júnior HT, Morris RE. Leflunomide and malononitrilamides. Am J Med Sci. 1997;313:289–301.
   Google Scholar
• Herrmann ML, Schleyerbach R, Kirschbaum BJ. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology. 2000;47:273–289.
   PubMed Web of Science ®Google Scholar
• O'Donnell EF, Saili KS, Koch DC, Kopparapu PR, Farrer D, Bisson WH, The anti-inflammatory drug leflunomide is an agonist of the aryl hydrocarbon receptor. PLoS One. 2010;5:e13128.
   PubMed Web of Science ®Google Scholar
• Leflunomide. In: AHFS Drug Information 2003. American Society of Health-System Pharmacists®, Bethesda; 2003. p. 3639–3644.
   Google Scholar
• Hamilton LC, Vojnovic I, Warner TD. A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-specific manner. Br J Pharmacol. 1999;127:1589–1596.
   Google Scholar
• Kehrer T, Blümlein K, Wozel G. Eotaxin release is suppressed by the metabolite A 77 1726 of the novel immunomodulating agent leflunomide. Eur J Allergy Clin Immunol. 2001;56:144.
   Google Scholar
• Pfeiffer C, Kehrer T, Wozel G. Suppression of eotaxin expression and release by leflunomide's active metabolite A77 1726 is not reversed by uridine, XXIII EAACI congress, Amsterdam; 2004. p. 12– 16.06.
   Google Scholar
• Manna SK, Mukhopadhyay A, Aggarwal BB. Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J Immunol. 2000;165:5962–5969.
   PubMed Web of Science ®Google Scholar
• Kale VP, Bichile LS. Leflunomide: a novel disease modifying anti-rheumatic drug. J Postgrad Med. 2004;50:154–157.
   Google Scholar
• Agarwal SK, Narsimulu G, Handa R. Leflunomide-The Indian Experience: a multicentre assessment of its safety and effectiveness in the treatment of active rheumatoid arthritis. J Indian Rheumatol Assoc. 2002;10:30–35.
   Google Scholar
• Li EK, Tam LS, Tomlinson B. Leflunomide in the treatment of rheumatoid arthritis. Clin Ther. 2004;26:447–459.
   PubMed Web of Science ®Google Scholar
• Jakez-Ocampo J, Richaud-Patin Y, Simón JA, Llorente L. Weekly dose of leflunomide for the treatment of refractory rheumatoid arthritis: an open pilot comparative study. Joint Bone Spine. 2002;69:307–311.
   PubMed Web of Science ®Google Scholar
• Frieling U, Luger TA. Mycophenolate mofetil and leflunomide: promising compounds for the treatment of skin diseases. Clin Exp Dermatol. 2002;27:562–570.
   PubMed Web of Science ®Google Scholar
• van Riel PL, Smolen JS, Emery P, Kalden JR, Dougados M, Strand CV, Leflunomide: a manageable safety profile. J Rheumatol Suppl. 2004;71:21–24.
   PubMedGoogle Scholar
• van Roon EN, Jansen TL, Houtman NM, Spoelstra P, Brouwers JR. Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity. Drug Saf. 2004;27:345–352.
   PubMed Web of Science ®Google Scholar
• Holm EA, Balslev E, Jemec GB. Vasculitis occurring during leflunomide therapy. Dermatology. 2001;203:258–259.
   PubMed Web of Science ®Google Scholar
• Chan AT, Bradlow A, McNally J. Leflunomide induced vasculitisea dose-response relationship. Rheumatology. 2003;42:492–493.
   Google Scholar
• Chan J, Sanders DC, Du L, Pillans PI. Leflunomide-associated pancytopenia with or without methotrexate. Ann Pharmacother. 2004;38:1206–1211.
   PubMed Web of Science ®Google Scholar
• Bharadwaj A, Haroon N. Peripheral neuropathy in patients on leflunomide. Rheumatology. 2004;43:934.
   PubMed Web of Science ®Google Scholar
• Bonnel RA, Graham DJ. Peripheral neuropathy in patients treated with leflunomide. Clin Pharmacol Ther. 2004;75:580–585.
   PubMed Web of Science ®Google Scholar
• Carulli MT, Davies UM. Peripheral neuropathy: an unwanted effect of leflunomide? Rheumatology. 2002;41:952–953.
   PubMed Web of Science ®Google Scholar
• Takeishi M, Akiyama Y, Akiba H, Adachi D, Hirano M, Mimura T. Leflunomide induced acute interstitial pneumonia. J Rheumatol. 2005;32:1160–1163.
   PubMed Web of Science ®Google Scholar
• Kamata Y, Nara H, Kamimura T, Haneda K, Iwamoto M, Masuyama J, Rheumatoid arthritis complicated with acute intersitial pneumonia induced by leflunomide as an adverse reaction. Intern Med. 2004;43:1201–1204.
   PubMed Web of Science ®Google Scholar
• Soliotis F, Glover M, Jawad AS. Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis. Ann Rheum Dis. 2002;61:850–851.
   Google Scholar
• Fischer TW, Bauer HI, Graefe T, Barta U, Elsner P. Erythema multiforme-like drug eruption with oral involvement after intake of leflunomide. Dermatology. 2003;207:386–389.
   Google Scholar
• Kerr OA, Murray CS, Tidman MJ. Subacute cutaneous lupus erythematosus associated with leflunomide. Clin Exp Dermatol. 2004;29:319–320.
   PubMed Web of Science ®Google Scholar
• Goeb V, Berhelot JM, Joly P, Mejjad O, de Quartrebarbes J, Reynaud-Hautin C, Leflunomide-induced subacute cutaneous lupus erythematosus. Rheumatology. 2005;44:823–824.
   PubMed Web of Science ®Google Scholar
• Gensburger D, Kawashima M, Marotte H, Kanitakis J, Miossec P. Lupus erythematosus with leflunomide: induction or reactivation? Ann Rheum Dis. 2005;64:153–155.
   PubMed Web of Science ®Google Scholar
• Behrens F, Koehm M, Burkhardt H. Update 2011: leflunomide in rheumatoid arthritis – strengths and weaknesses. Curr Opin Rheumatol. 2011;23:282–287.
   PubMedGoogle Scholar
• Arava (leflunomide) Prescribing information as of September 2003. Aventis Pharmaceuticals, Inc. Kansas City, MO 64137.
   Google Scholar
• Veeranna S, Jayadev B, Kushalappa PA. Severe cutaneous adverse drug reaction to leflunomide: a report of 5 cases. Indian J Dermatol Venereol Leprol. 2006;72:286–289.
   Google Scholar
• Annonymous. National health services (NHS), Shared Care Guidelines. Leflunomide – monitoring protocol, updated on January 28th, 2011. England.
   Google Scholar
• Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, Treatment of Psoriatic Arthritis Study Group. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 2004;50:1939–1950.
   PubMed Web of Science ®Google Scholar
• Malesci D, Tirri R, Buono R, La Montagna G. Leflunomide in psoriatic arthritis: a retrospective study of discontinuation rate in daily clinical practice compared with methotrexate. Clin Exp Rheumatol. 2007;25:881–884.
   PubMed Web of Science ®Google Scholar
• Liang GC, Barr WG. Open trial of leflunomide for refractory psoriasis and psoriatic arthritis. J Clin Rheumatol. 2001;7:366–370.
   PubMed Web of Science ®Google Scholar
• Ravindran V, Scott DL, Choy EH. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann Rheum Dis. 2008;67:855–859.
   PubMed Web of Science ®Google Scholar
• Tlacuilo-Parra JA, Guevara-Gutiérrez E, Rodríguez-Castellanos MA, Ornelas-Aguirre JM, Barba-Gómez JF, Salazar-Páramo M. Leflunomide in the treatment of psoriasis: results of a phase II open trial. Br J Dermatol. 2004;150:970–976.
   PubMed Web of Science ®Google Scholar
• Schmitt J, Wozel G, Pfeiffer C. Leflunomide as a novel treatment option in severe atopic dermatitis. Br J Dermatol. 2004;150:1182–1185.
   Google Scholar
• Wozel G, Vitéz L, Pfeiffer C. Severe atopic dermatitis and leflunomide: first clinical experience and highlights of pertinent experimental data. Dermatol Online J. 2006;12:6.
   PubMedGoogle Scholar
• Tam LS, Li EK, Wong CK, Lam CW, Szeto CC. Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus. 2004;13:601–604.
   PubMed Web of Science ®Google Scholar
• Remer CF, Weisman MH, Wallace DJ. Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus. 2001;10:480–483.
   PubMed Web of Science ®Google Scholar
• Bremer JP, Ullrich S, Laudien M, Gross WL, Lamprecht P. Methotrexate plus leflunomide for the treatment of relapsing Wegener's granulomatosis. A retrospective uncontrolled study. Clin Exp Rheumatol. 2010;28:67–71.
   PubMed Web of Science ®Google Scholar
• Metzler C, Miehle N, Manger K, Iking-Konert C, de Groot K, Hellmich B, Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology. 2007;46:1087–1091.
   PubMed Web of Science ®Google Scholar
• Metzler C, Fink C, Lamprecht P, Gross WL, Reinhold-Keller E. Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology. 2004;43:315–320.
   PubMed Web of Science ®Google Scholar
• Henes JC, Fritz J, Koch S, Klein R, Horger M, Risler T, Rituximab for treatment-resistant extensive Wegener's granulomatosis–additive effects of a maintenance treatment with leflunomide. Clin Rheumatol. 2007;26:1711–1715.
   PubMed Web of Science ®Google Scholar
• van Woerkom JM, Kruize AA, Geenen R, van Roon EN, Goldschmeding R, Verstappen SM, Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study. Ann Rheum Dis. 2007;66:1026–1032.
   PubMed Web of Science ®Google Scholar
• Nousari HC, Anhalt GJ. Bullous pemphigoid treated with leflunomide: a novel immunomodulatory agent. Arch Dermatol. 2000;136:1204–1205.
   PubMedGoogle Scholar
• Boswell JS, Costner MI. Leflunomide as adjuvant treatment of dermatomyositis. J Am Acad Dermatol. 2008;58:403–406.
   PubMed Web of Science ®Google Scholar
• Majithia V, Sanders S, Harisdangkul V, Wilson JG. Successful treatment of sarcoidosis with leflunomide. Rheumatology. 2003;42:700–702.
   PubMed Web of Science ®Google Scholar
• Sebastiani M, Giuggioli D, Vesprini E, Caruso A, Ferri C. Successful treatment with leflunomide of arthritis in systemic sclerosis patients. Rheumatology. 2006;45:1175–1176.
   Google Scholar
• Scarpato S, Tirri E. Successful treatment of SAPHO syndrome with leflunomide. Report of two cases. Clin Exp Rheumatol. 2005;23:731.
   Google Scholar
• Reich K, Hummel KM, Beckmann I, Mössner R, Neumann C. Treatment of severe psoriasis and psoriatic arthritis with leflunomide. Br J Dermatol. 2002;146:335–336.
   PubMed Web of Science ®Google Scholar
• Melwani PM, Peñate Y, Guillermo N, Soler E, Hernández-Machín B, Borrego L. Leflunomide in the treatment of palmoplantar pustulosis. Arch Dermatol. 2009;145:1224–1226.
   PubMedGoogle Scholar
• Fox RI, Herrmann ML, Frangou CG, Wahl GM, Morris RE, Strand V, Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol. 1999;93:198–208.
   PubMed Web of Science ®Google Scholar